Assertio Holdings, Inc.
ASRT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ASRT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ASRT
Assertio Holdings, Inc. is a pharmaceutical company focused on commercializing Rolvedon® (eflapegrastim) and other specialty products, with a recent emphasis on oncology and a simplified corporate structure.
Key risk: Nasdaq compliance risk
BioSniper Score
Based on 5 of 6 signals
Market Cap
$151.9M
Cash Runway
—
Lead Asset
poziotinib (Phase 2)Next Catalyst
Patent_Expiry · Feb 24, 2029Financial data as of Mar 31, 2026.
Tracking 2 pipeline candidates · 9 clinical trials · 1 catalyst for Assertio Holdings, Inc..
Assertio Holdings, Inc. is a pharmaceutical company focused on commercializing Rolvedon® (eflapegrastim) and other specialty products, with a recent emphasis on oncology and a simplified corporate structure.
- Reported total revenue of $9.9M and a net loss of -$18.9M for the period ended 2026-03-31 [sec].
- Cash and equivalents of $33.7M, shareholders' equity of $94.0M, and total debt of $39.2M as of 2026-03-31 [sec].
- Key asset Rolvedon® (eflapegrastim) was acquired via the Spectrum Merger, entering the oncology marketplace [sec · filed 2024-04-19].
- A Phase II study of diclofenac salvage in metastatic non-small cell lung cancer is recruiting, with a primary endpoint of clinical benefit rate [catalyst].
- The company faces ongoing risks from generic competition and the need to maintain Nasdaq compliance due to stock trading near $1.00 [sec · filed 2024-11-12].
What works
- Diversified asset base with Rolvedon® in oncology, supported by a non-personal commercial platform and digital tools [sec · filed 2024-04-19].
- Generated $49.6M in operating cash flow in fiscal 2023, indicating prior operational cash generation [sec · filed 2024-04-19].
- Ongoing efforts to simplify corporate structure and consolidate operations may yield operating efficiencies [sec_mda · as of 2025-11-10].
What to weigh
- Recurring net operating losses have led to a full valuation allowance against deferred tax assets, limiting future NOL benefits [sec_mda · as of 2026-03-16].
- Ceased commercialization of Otrexup in July 2025, with potential payments and loss of product revenue [sec_mda · as of 2026-03-16].
- Stock trading near $1.00 per share and short seller activity create risk of Nasdaq delisting [sec · filed 2024-11-12].
- Generic competition and other competitive products pose a threat to revenue from existing products [sec_mda · as of 2026-03-16].
From the filings
Quoted directly from source documents.
The company has a Phase II study recruiting for diclofenac salvage in NSCLC.
“Phase 2 Start: Phase II Study of Diclofenac Salvage in Patients Metastatic Non-Small Cell Lung Cancer With Early Si - NCT: NCT06731270. Status: Recruiting.”
Catalysts
The company completed the Spectrum Merger and acquired Rolvedon.
“Completed the Spectrum Merger and its key asset Rolvedon®, diversifying the Company's asset base and entering the oncology marketplace.”
SEC filings · April 19, 2024
Catalyst timeline
- 2029-02-24 · Patent_Expiry · ZIPSOR — Patent/exclusivity expiry for ZIPSOR may open the door to generic competition.
Risks & what to watch (4)›
Key risks
- Nasdaq compliance risk — Stock trading near $1.00 and short seller activity may lead to delisting [sec · filed 2024-11-12].
- Generic competition — Entry of generics and competitive products could reduce revenue [sec_mda · as of 2026-03-16].
- Net operating loss limitations — Full valuation allowance on deferred tax assets may limit future NOL benefits [sec_mda · as of 2026-03-16].
- Otrexup discontinuation — Ceased commercialization in July 2025, with potential payments and lost revenue [sec_mda · as of 2026-03-16].
What to watch
- Progress of the Phase II diclofenac salvage study in NSCLC (NCT06731270) [catalyst].
- Ability to maintain Nasdaq listing compliance amid stock price volatility [sec · filed 2024-11-12].
- Impact of generic competition on Rolvedon and other product revenues [sec_mda · as of 2026-03-16].
- Execution of corporate simplification and potential cost savings [sec_mda · as of 2025-11-10].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Assertio Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Assertio Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 1.79 · 0% dilution
Lead: Approved
2 candidates
1 upcoming, next in ~909d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
64
Total value held
$37.0M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 537,904 | $10.3M |
| renaissance technologies llc | 228,599 | $4.4M |
| susquehanna international group, llp | 181,600 | $3.5M |
| edgewood management llc | 107,517 | $2.0M |
| blackrock, inc. | 90,035 | $1.7M |
| jane street group, llc | 79,436 | $1.5M |
| geode capital management, llc | 76,314 | $1.5M |
| citadel advisors llc | 74,562 | $1.4M |
| sei investments co | 54,940 | $1.0M |
| huntleigh advisors, inc. | 52,603 | $1.0M |
Showing top 10 of 64 institutional holders of Assertio Holdings, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 4.6%
- Days to cover
- 1.1
- Shares short
- 289,282
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ASRT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Assertio Holdings, Inc.?
Assertio Holdings, Inc. is a pharmaceutical company focused on commercializing Rolvedon® (eflapegrastim) and other specialty products, with a recent emphasis on oncology and a simplified corporate structure.
What is Assertio Holdings, Inc.'s lead drug candidate?
Assertio Holdings, Inc.'s most advanced tracked candidate is poziotinib (Phase 2) for Under investigation for non-small cell lung cancer tumors with various mutations..
What is Assertio Holdings, Inc.'s next catalyst?
Assertio Holdings, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: ZIPSOR" — expected February 24, 2029.
Who is the CEO of Assertio Holdings, Inc.?
Mr. Mark L. Reisenauer is the chief executive officer of Assertio Holdings, Inc. (ASRT).
Where is Assertio Holdings, Inc. headquartered?
Assertio Holdings, Inc. (ASRT) is headquartered in Lake Forest, IL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.